Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle...
https://pubmed.ncbi.nlm.nih.gov/39191779/Actively Recruiting
Led by West China Hospital · Updated on 2026-10-02
40
Participants Needed
9
Research Sites
260 weeks
Total Duration
Researchers are evaluating a new neoadjuvant treatment approach for patients with resectable stage IB to IIIB non-small cell lung cancer NSCLC. This prospective Phase II study aims to assess the effectiveness and safety of combining CT-guided Cryo-Thermal Ablation with toripalimab and platinum-based doublet chemotherapy before surgery. The study focuses on improving major pathological response rates since many patients currently do not achieve a complete response with chemoimmunotherapy alone. Participants will first undergo a CT-guided Cryo-Thermal Ablation procedure targeting the primary lung tumor. After that, they will receive three planned cycles of toripalimab, an anti-PD-1 monoclonal antibody, combined with platinum-based doublet chemotherapy administered every three weeks. Following these treatments, patients will have a preoperative reassessment before undergoing curative-intent surgical removal of the tumor. The study includes about 40 participants and is conducted across multiple centers. During the trial, participants will be closely monitored through pathological evaluations of surgical specimens, imaging assessments, and health-related quality of life questionnaires. Researchers will measure outcomes such as pathological complete response rate, major pathological response rate, objective response rate, event-free survival, overall survival, and treatment-emergent adverse events. Additional exploratory analyses will examine immune responses and molecular changes using advanced genomic and proteomic techniques. The total follow-up period may extend up to approximately five years to assess long-term outcomes.
CONDITIONS
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
B
Beinuo Wang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 9 weeks
Participants undergo CT-guided Cryo-Thermal Ablation of the lung tumor, followed by three cycles of intravenous toripalimab combined with platinum-based doublet chemotherapy every three weeks. After treatment, a preoperative reassessment is performed before surgery.
3 treatment visits every 3 weeks plus preoperative reassessment visit
Duration - 1 day to 1 week
Participants receive curative-intent surgical removal of the lung tumor approximately 4 to 6 weeks after completing neoadjuvant treatment.
Surgery visit and postoperative follow-up visits
Duration - Up to 5 years
Participants are monitored for up to 5 years after surgery to assess survival outcomes, treatment side effects, and quality of life.
Periodic follow-up visits and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle...
https://pubmed.ncbi.nlm.nih.gov/39191779/Sijia Gu, Qiyu Luo, Yalei Zhang...
https://pubmed.ncbi.nlm.nih.gov/41176543/Zedao Liu, Zhenlin Yang, Junqi Wu...
https://pubmed.ncbi.nlm.nih.gov/40147443/Shun Lu, Wei Zhang, Lin Wu...
https://pubmed.ncbi.nlm.nih.gov/38227033/Amanda Leiter, Rajwanth R Veluswamy, Juan P Wisnivesky
https://pubmed.ncbi.nlm.nih.gov/37479810/West China Hospital
Lead Sponsor